Abstract
Introduction: it was to demonstrate effects of methylprednisolone (MPS) and azithromycin treatment on serum biochemical factors and their impact on Serum Biochemical Factors (CRP, PCT, IL-6, TNF-α ) prognosis in patients with viral pneumonia (VP). Methods: 120 patients with VP admitted to our hospital were rolled into control (Ctrl), low-dose (80 mg MPS, L-MPS), medium-dose (500 mg MPS, M-MPS), and high-dose (1000 mg MPS, H-MPS) groups. The therapeutic efficacy of each group was evaluated. C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) were detected. Pulmonary function parameters were assessed using a pulmonary function testing device. Adverse reactions (ARs) such as fever, nausea, vomiting, and gastrointestinal bleeding post-treatment were recorded.
Results: total effective rate (TER) post-treatment in Ctrl group was 60.00%, which was inferior to that in L-MPS group (76.67%), M-MPS group (90.00%), and H-MPS group (93.33%) (P<0.05). Disappearance time of CRP, PCT, IL-6, TNF-α, fever, cough, and X-ray infiltrates was reduced in L-MPS, M-MPS, and H-MPS groups relative to Ctrl group (P<0.05), while FVC, MMEF, and PEF were increased (P<0.05). Disappearance time of CRP, PCT, IL-6, TNF-α, fever, cough, and X-ray infiltrates in M-MPS and H-MPS groups was inferior to that in L-MPS group (P<0.05), while FVC, MMEF, and PEF were higher (P<0.05).
Conclusion: medium-dose (80 mg) MPS combined with azithromycin greatly reduces inflammatory cytokine levels, shortens the time to clinical symptom relief, improves lung function and respiratory capacity, demonstrating significant efficacy in treating VP.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.